You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of July 29, 2019

  • Discovery Projects
  • Phase 1
    35
  • Phase 2
    34
  • Phase 3
    23
  • Registration
    9
  • Total101
 
Compound Name
Indication
Phase
Submission Type
Compound Typesort descending
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridium difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections Phase 2 New Molecular Entity Vaccine
PF-06753512
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive Group B streptococcus infection Phase 1 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY meningococcal infections Phase 1 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection Phase 1 New Molecular Entity Vaccine
PF-06936308
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Multiple Cancers Phase 1 New Molecular Entity Vaccine
crisaborole (PF-06940799)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PDE4 Inhibitor
Go to clinical trial
Atopic Dermatitis (E.U.) Registration New Molecular Entity Small Molecule
tafamidis meglumine
Therapeutic Area:
Rare Diseases
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Transthyretin (TTR) Dissociation Inhibitor
Go to clinical trial
Transthyretin familial amyloid polyneuropathy (U.S.) (FAST TRACK, ORPHAN - U.S.) Registration New Molecular Entity Small Molecule
Vyndaqel (tafamidis meglumine and free acid)
Therapeutic Area:
Rare Diseases
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Transthyretin (TTR) Dissociation Inhibitor
Go to clinical trial
Transthyretin Amyloid Cardiomyopathy (E.U.) ORPHAN - E.U.) Registration Product Enhancement Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Modified Release 11mg Tablet for Rheumatoid Arthritis (E.U.) Registration Product Enhancement Small Molecule
aztreonam-avibactam (PF-06947387)
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Beta Lactam/Beta Lactamase Inhibitor
Go to clinical trial
Treatment of infections caused by Gram-negative bacteria for which there are limited or no treatment options Phase 3 New Molecular Entity Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.)
Project advanced
Registration New Molecular Entity Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Metastatic Hormone Sensitive Prostate Cancer (E.U.)
Project advanced
Registration Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Early Breast Cancer in Adjuvant Setting Phase 3 Product Enhancement Small Molecule